212 related articles for article (PubMed ID: 21804067)
1. Enhancement by LDL of transfer of L-4F and oxidized lipids to HDL in C57BL/6J mice and human plasma.
Meriwether D; Imaizumi S; Grijalva V; Hough G; Vakili L; Anantharamaiah GM; Farias-Eisner R; Navab M; Fogelman AM; Reddy ST; Shechter I
J Lipid Res; 2011 Oct; 52(10):1795-809. PubMed ID: 21804067
[TBL] [Abstract][Full Text] [Related]
2. An apoA-I mimetic peptide containing a proline residue has greater in vivo HDL binding and anti-inflammatory ability than the 4F peptide.
Wool GD; Vaisar T; Reardon CA; Getz GS
J Lipid Res; 2009 Sep; 50(9):1889-900. PubMed ID: 19433476
[TBL] [Abstract][Full Text] [Related]
3. High-density lipoprotein and 4F peptide reduce systemic inflammation by modulating intestinal oxidized lipid metabolism: novel hypotheses and review of literature.
Navab M; Reddy ST; Van Lenten BJ; Buga GM; Hough G; Wagner AC; Fogelman AM
Arterioscler Thromb Vasc Biol; 2012 Nov; 32(11):2553-60. PubMed ID: 23077141
[TBL] [Abstract][Full Text] [Related]
4. Apolipoprotein A-I mimetic peptide helix number and helix linker influence potentially anti-atherogenic properties.
Wool GD; Reardon CA; Getz GS
J Lipid Res; 2008 Jun; 49(6):1268-83. PubMed ID: 18323574
[TBL] [Abstract][Full Text] [Related]
5. The effect of HDL mimetic peptide 4F on PON1.
Vakili L; Hama S; Kim JB; Tien D; Safarpoor S; Ly N; Vakili G; Hough G; Navab M
Adv Exp Med Biol; 2010; 660():167-72. PubMed ID: 20221879
[TBL] [Abstract][Full Text] [Related]
6. L-4F differentially alters plasma levels of oxidized fatty acids resulting in more anti-inflammatory HDL in mice.
Imaizumi S; Grijalva V; Navab M; Van Lenten BJ; Wagner AC; Anantharamiah GM; Fogelman AM; Reddy ST
Drug Metab Lett; 2010 Aug; 4(3):139-48. PubMed ID: 20642447
[TBL] [Abstract][Full Text] [Related]
7. Effects of D-4F on vasodilation and vessel wall thickness in hypercholesterolemic LDL receptor-null and LDL receptor/apolipoprotein A-I double-knockout mice on Western diet.
Ou J; Wang J; Xu H; Ou Z; Sorci-Thomas MG; Jones DW; Signorino P; Densmore JC; Kaul S; Oldham KT; Pritchard KA
Circ Res; 2005 Nov; 97(11):1190-7. PubMed ID: 16224061
[TBL] [Abstract][Full Text] [Related]
8. In vitro stimulation of HDL anti-inflammatory activity and inhibition of LDL pro-inflammatory activity in the plasma of patients with end-stage renal disease by an apoA-1 mimetic peptide.
Vaziri ND; Moradi H; Pahl MV; Fogelman AM; Navab M
Kidney Int; 2009 Aug; 76(4):437-44. PubMed ID: 19471321
[TBL] [Abstract][Full Text] [Related]
9. Apolipoprotein A-I mimetic peptides: a potential new therapy for the prevention of atherosclerosis.
Sherman CB; Peterson SJ; Frishman WH
Cardiol Rev; 2010; 18(3):141-7. PubMed ID: 20395699
[TBL] [Abstract][Full Text] [Related]
10. A novel method for oral delivery of apolipoprotein mimetic peptides synthesized from all L-amino acids.
Navab M; Ruchala P; Waring AJ; Lehrer RI; Hama S; Hough G; Palgunachari MN; Anantharamaiah GM; Fogelman AM
J Lipid Res; 2009 Aug; 50(8):1538-47. PubMed ID: 19225094
[TBL] [Abstract][Full Text] [Related]
11. Systemic inflammation, intestine, and paraoxonase-1.
Vakili L; Navab KD; Shabihkhani M; Pourtabatabaei N; Vazirian S; Barseghian Z; Seyedali S; Hough G
Adv Exp Med Biol; 2014; 824():83-8. PubMed ID: 25038995
[TBL] [Abstract][Full Text] [Related]
12. Oral D-4F causes formation of pre-beta high-density lipoprotein and improves high-density lipoprotein-mediated cholesterol efflux and reverse cholesterol transport from macrophages in apolipoprotein E-null mice.
Navab M; Anantharamaiah GM; Reddy ST; Hama S; Hough G; Grijalva VR; Wagner AC; Frank JS; Datta G; Garber D; Fogelman AM
Circulation; 2004 Jun; 109(25):3215-20. PubMed ID: 15197147
[TBL] [Abstract][Full Text] [Related]
13. An oral apoJ peptide renders HDL antiinflammatory in mice and monkeys and dramatically reduces atherosclerosis in apolipoprotein E-null mice.
Navab M; Anantharamaiah GM; Reddy ST; Van Lenten BJ; Wagner AC; Hama S; Hough G; Bachini E; Garber DW; Mishra VK; Palgunachari MN; Fogelman AM
Arterioscler Thromb Vasc Biol; 2005 Sep; 25(9):1932-7. PubMed ID: 15961700
[TBL] [Abstract][Full Text] [Related]
14. L-4F alters hyperlipidemic (but not healthy) mouse plasma to reduce platelet aggregation.
Buga GM; Navab M; Imaizumi S; Reddy ST; Yekta B; Hough G; Chanslor S; Anantharamaiah GM; Fogelman AM
Arterioscler Thromb Vasc Biol; 2010 Feb; 30(2):283-9. PubMed ID: 19965777
[TBL] [Abstract][Full Text] [Related]
15. The apolipoprotein A-I mimetic peptide, D-4F, alleviates ox-LDL-induced oxidative stress and promotes endothelial repair through the eNOS/HO-1 pathway.
Liu D; Ding Z; Wu M; Xu W; Qian M; Du Q; Zhang L; Cui Y; Zheng J; Chang H; Huang C; Lin D; Wang Y
J Mol Cell Cardiol; 2017 Apr; 105():77-88. PubMed ID: 28274624
[TBL] [Abstract][Full Text] [Related]
16. 5A apolipoprotein mimetic peptide promotes cholesterol efflux and reduces atherosclerosis in mice.
Amar MJ; D'Souza W; Turner S; Demosky S; Sviridov D; Stonik J; Luchoomun J; Voogt J; Hellerstein M; Sviridov D; Remaley AT
J Pharmacol Exp Ther; 2010 Aug; 334(2):634-41. PubMed ID: 20484557
[TBL] [Abstract][Full Text] [Related]
17. Sidedness of interfacial arginine residues and anti-atherogenicity of apolipoprotein A-I mimetic peptides.
Nayyar G; Mishra VK; Handattu SP; Palgunachari MN; Shin R; McPherson DT; Deivanayagam CCS; Garber DW; Segrest JP; Anantharamaiah GM
J Lipid Res; 2012 May; 53(5):849-858. PubMed ID: 22377531
[TBL] [Abstract][Full Text] [Related]
18. Influenza infection promotes macrophage traffic into arteries of mice that is prevented by D-4F, an apolipoprotein A-I mimetic peptide.
Van Lenten BJ; Wagner AC; Anantharamaiah GM; Garber DW; Fishbein MC; Adhikary L; Nayak DP; Hama S; Navab M; Fogelman AM
Circulation; 2002 Aug; 106(9):1127-32. PubMed ID: 12196340
[TBL] [Abstract][Full Text] [Related]
19. Human apolipoprotein A-I and A-I mimetic peptides: potential for atherosclerosis reversal.
Navab M; Anantharamaiah GM; Reddy ST; Van Lenten BJ; Datta G; Garber D; Fogelman AM
Curr Opin Lipidol; 2004 Dec; 15(6):645-9. PubMed ID: 15529023
[TBL] [Abstract][Full Text] [Related]
20. Apolipoprotein E mimetic is more effective than apolipoprotein A-I mimetic in reducing lesion formation in older female apo E null mice.
Nayyar G; Garber DW; Palgunachari MN; Monroe CE; Keenum TD; Handattu SP; Mishra VK; Anantharamaiah GM
Atherosclerosis; 2012 Oct; 224(2):326-31. PubMed ID: 22771190
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
